Page 77 - CSIR-IGIB Annual Report 2020-21
P. 77
Non-coding RNAs and epigenetic mechanisms project aims to re-engineer keratinocytes by
Skeletal muscles of normal and obese diabetic ectopically altering levels of these altered
animals were used to quantify levels of miR- molecules and study the effects on wound
449a, miR-539 and the lncRNA H19. closure. Towards this, experiments were done
Overexpression of miR-449a and miR-539 in using the HaCaT human keratinocyte cell line
C2C12 muscle cells preliminarily demonstrated where it was observed that use of miR-497 that
them to be targeting HDAC6 and DNMT-3b, significantly increased cellular miR-497 levels,
respectively. H19 inhibition significantly promoted a modest increase of wound closure
increased levels of HDACs, suggesting a while the miR-497 inhibitor led to a time
regulation of these epigenetic modifiers by dependent inhibition in wound closure as was
ncRNAs. From a list of previously identified observed in a scratch assay in HaCaT cells. Also,
differentially expressed genes, attempts were since Dicer levels are downregulated in a
made to study the correlation of the ncRNA- delayed wound healing during diabetes, in an
DNMT/HDAC regulation on the altered genes, if attempt to assess the potential of Dicer in
any. A set of genes belonging to the wound closure, a scratch was made in control
AMPK/insulin signaling pathways were found to and Dicer transfected cells, there was increased
be affected; these also possess CpG islands and cell migration as well as proliferation, and
histone acetylation marks. significant closure of the wound area in the
Dicer transfected cells compared to the control
Cell-based therapies cells. These indicate a potential role of these
Previous work had demonstrated several molecules in wound closure. These are being
miRNAs and the pre-miRNA processing enzyme- investigated in detail together with toxicity
Dicer, to be significantly down-regulated in the assays and in vivo validation.
stalled wound healing during diabetes. This
Publications
LncRNAs in cancer: Regulatory and therapeutic implications. Nandwani A, Rathore S, Datta M. Cancer Lett. 2021
Mar 31;501:162-171.
Annual Report 2020-21 74